Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and typically fatal lung
disease characterised by subpleural fibrosis, subepithelial fibroblast foci, and microscopic …

Angiotensin II (ANGII) has been identified as a proapoptotic and profibrotic factor in
experimental lung fibrosis models, and patients with the ID/DD polymorphism of ANG …

A large body of evidence demonstrates that angiotensin II and angiotensin receptors are
required for the pathogenesis of experimental lung fibrosis. Angiotensin has a number of …

Background: This American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior …

Background At present, no approved pharmacotherapies are available for unclassifiable
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …

Rationale: The impact of coronavirus disease (COVID-19) on patients with interstitial lung
disease (ILD) has not been established. Objectives: To assess outcomes in patients with ILD …

Rationale: Idiopathic pulmonary fibrosis (IPF) is a complex lung disease characterized by
scarring of the lung that is believed to result from an atypical response to injury of the …

Earlier work from this laboratory showed that local generation of angiotensin (ANG) II is
required for the pathogenesis of experimental pulmonary fibrosis and that ANG peptides are …

Importance There is a major need for effective, well-tolerated treatments for idiopathic
pulmonary fibrosis (IPF). Objective To assess the efficacy and safety of the autotaxin inhibitor …

Background Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal
fibrotic disorder, with no curative therapies. The signal transducer and activator of …